Objective      To investigate the correlation of the expression of S100A2 with 2 key molecules of wnt/β-catenin signaling pathway

β-catenin and pGSK-3β in human colon cancer and their clinical significance.       Methods       Expression of S100A2

β-catenin and pGSK-3β in 42 colon cancer tissue samples was detected by immunohistochemical assay and Western blotting. Their relation with the clinicopathological characteristics of colon cancer was studied

and their correlation was analyzed by Pearson rank analysis.       Results      Immunohistochemistry demonstrated that S100A2 and β-catenin were mainly located in the cancer cells nuclear and/or cytoplasm

while pGSK-3β was located in the cytoplasm. Western blotting showed that the expression of S100A2

β-catenin and pGSK-3β was significantly higher in tumor tissue than normal tissue (P0.01). Meanwhile

the expression was markedly higher in Dukes stage C+D than in Dukes A+B (P0.01)

in the cases with lymph node metastasis than those without metastasis (P0.01). The expression of S100A2 was positively related with that of β-catenin and GSK-3β

respectively （r=0.637，P0.01; r=0.626，P0.01).       Conclusion      S100A2 may participate in the incidence and development of colon cancer via adjusting the key molecules of Wnt/ β-catenin pathway.